Drreddys Laboratories | RDY - Operating Expenses


Drreddys Laboratories reported INR72.94B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Bayer EUR 9.88B 452M Mar/2026
Canopy Growth CAD 87.2M 6.22M Dec/2025
Cipla INR 60.98B 1.06B Dec/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Novartis USD 9.29B 507M Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Richter Gedeon HUF 151.11B 20.72B Sep/2025
Sun Pharmaceuticals INR 111.11B 6.97B Sep/2025
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026